成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

  1. Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Cell Cycle/DNA Damage Autophagy Anti-infection
  2. RAR/RXR PPAR Autophagy Bacterial
  3. Magnolol

Magnolol  (Synonyms: 厚樸酚)

目錄號: HY-N0163 純度: 99.92%
COA 產(chǎn)品使用指南

Magnolol 是從厚樸的樹皮中分到的木脂素,為 RXRαPPARγ 的雙重激動劑,EC50 值分別為 10.4 μM 和 17.7 μM。

MCE 的所有產(chǎn)品僅用作科學研究或藥證申報,我們不為任何個人用途提供產(chǎn)品和服務

Magnolol Chemical Structure

Magnolol Chemical Structure

CAS No. : 528-43-8

1.  客戶無需承擔相應的運輸費用。

2.  同一機構(gòu)(單位)同一產(chǎn)品試用裝僅限申領(lǐng)一次,同一機構(gòu)(單位)一年內(nèi)

     可免費申領(lǐng)三個不同產(chǎn)品的試用裝。

3.  試用裝只面向終端客戶

規(guī)格 價格 是否有貨 數(shù)量
10 mM * 1 mL in DMSO ¥457
In-stock
1 mg ¥156
In-stock
5 mg ¥312
In-stock
10 mg ¥500
In-stock
25 mg ¥850
In-stock
50 mg ¥1300
In-stock
100 mg ¥1900
In-stock
500 mg ¥4863
In-stock
1 g   詢價  
5 g   詢價  

* Please select Quantity before adding items.

Other Forms of Magnolol:

查看 RAR/RXR 亞型特異性產(chǎn)品:

查看 PPAR 亞型特異性產(chǎn)品:

  • 生物活性

  • 實驗參考方法

  • 純度 & 產(chǎn)品資料

  • 參考文獻

生物活性

Magnolol, a natural lignan isolated from the stem bark of Magnolia officinalis, is a dual agonist of both RXRα and PPARγ, with EC50 values of 10.4 μM and 17.7 μM, respectively.

IC50 & Target[1]

PPARγ

17.7 μM (EC50)

細胞效力
(Cellular Effect)
Cell Line Type Value Description References
A549 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
A549 IC50
> 5 μg/mL
Compound: 5
Cytotoxicity against human A549 cells by MTT assay
Cytotoxicity against human A549 cells by MTT assay
[PMID: 17918910]
A549 IC50
> 80 μM
Compound: MAG
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32044229]
A549 IC50
> 80 μM
Compound: Magnolol
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human A549 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
A549 IC50
57.36 μM
Compound: 12; ML
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells after 72 hrs by MTT assay
[PMID: 30006164]
A549 IC50
82.4 μM
Compound: Magnolol
Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human A549 cells expressing wild type EGFR assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
AGS IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human AGS cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
BV-2 IC50
14.9 μg/mL
Compound: 9
Inhibition of NADPH oxidase-mediated ROS production in LPS-stimulated mouse BV2 cells after 20 mins by flow cytometry
Inhibition of NADPH oxidase-mediated ROS production in LPS-stimulated mouse BV2 cells after 20 mins by flow cytometry
[PMID: 19086868]
CHO EC50
18.3 μM
Compound: 3
Partial agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940
Partial agonist activity at recombinant human CB1 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940
[PMID: 24900561]
CHO EC50
3.28 μM
Compound: 3
Partial agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940
Partial agonist activity at recombinant human CB2 receptor expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 100 uM after 5 mins by cAMP-competition binding assay relative to CP55,940
[PMID: 24900561]
HCC827 IC50
> 40 μM
Compound: 12; ML
Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay
Antiproliferative activity against human HCC827 cells after 72 hrs by MTT assay
[PMID: 30006164]
HCC827 IC50
94.65 μM
Compound: Magnolol
Antiproliferative activity against human HCC827 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human HCC827 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
HEK293 IC50
> 80 μM
Compound: Magnolol
Antiproliferative activity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HEK293 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
HeLa IC50
> 5 μg/mL
Compound: 5
Cytotoxicity against human HeLa cells by MTT assay
Cytotoxicity against human HeLa cells by MTT assay
[PMID: 17918910]
HeLa IC50
> 80 μM
Compound: Magnolol
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human HeLa cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
HepG2 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human HepG2 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
HepG2 2.2.15 IC50
2.03 μM
Compound: 5
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBsAg secretion after 12 days by ELISA
[PMID: 23434030]
HepG2 2.2.15 IC50
3.76 μM
Compound: 5
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBeAg secretion after 12 days by ELISA
[PMID: 23434030]
HepG2 2.2.15 CC50
63.68 μM
Compound: 5
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
Cytotoxicity against human HepG2(2.2.15) cells after 12 days by MTT assay
[PMID: 23434030]
HepG2 2.2.15 IC50
8.67 μM
Compound: 5
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
Antiviral activity against Hepatitis B virus infected in human HepG2.2.15 cells assessed as inhibition of HBV DNA replication after 72 hrs by PCR analysis
[PMID: 23434030]
HL-60 IC50
48 μM
Compound: 1
Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human HL60 cells after 48 hrs by sulforhodamine B assay
[PMID: 22424614]
HONE1 cell line IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human HONE1 cell line assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
K562 IC50
> 5 μg/mL
Compound: 5
Cytotoxicity against human K562 cells by MTT assay
Cytotoxicity against human K562 cells by MTT assay
[PMID: 17918910]
L02 IC50
> 80 μM
Compound: Magnolol
Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human LO2 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
LoVo IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human LoVo cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
MCF7 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
MCF7 IC50
> 80 μM
Compound: Magnolol
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human MCF7 cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
MDA-MB-231 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
MOLT-4 IC50
58 μM
Compound: 1
Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human MOLT4 cells after 48 hrs by sulforhodamine B assay
[PMID: 22424614]
NCI-H1299 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1299 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
NCI-H1650 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H1650 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
NCI-H1650 IC50
56.65 μM
Compound: 12; ML
Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1650 cells after 72 hrs by MTT assay
[PMID: 30006164]
NCI-H1650 IC50
66.3 μM
Compound: Magnolol
Antiproliferative activity against human NCI-H1650 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1650 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
NCI-H1975 IC50
> 40 μM
Compound: 12; ML
Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1975 cells after 72 hrs by MTT assay
[PMID: 30006164]
NCI-H1975 IC50
87.28 μM
Compound: Magnolol
Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H1975 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
NCI-H358 IC50
61.23 μM
Compound: 12; ML
Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H358 cells after 72 hrs by MTT assay
[PMID: 30006164]
NCI-H441 IC50
58.68 μM
Compound: 12; ML
Antiproliferative activity against human H441 cells after 72 hrs by MTT assay
Antiproliferative activity against human H441 cells after 72 hrs by MTT assay
[PMID: 30006164]
NCI-H441 IC50
65.8 μM
Compound: Magnolol
Antiproliferative activity against human NCI-H441 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H441 cells expressing EGFR mutant assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
NCI-H460 IC50
> 40 μM
Compound: 12; ML
Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
Antiproliferative activity against human H460 cells after 72 hrs by MTT assay
[PMID: 30006164]
NCI-H460 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
NCI-H460 IC50
> 80 μM
Compound: MAG
Antiproliferative activity against human H460 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human H460 cells assessed as inhibition of cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32044229]
NCI-H460 IC50
95.57 μM
Compound: Magnolol
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
Antiproliferative activity against human NCI-H460 cells assessed as reduction in cell viability after 72 hrs by MTT assay
[PMID: 33069436]
Oocyte EC50
36.8 μM
Compound: Magnolol
Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique
Modulation of GABA Aalpha1beta2 receptor expressed in Xenopus laevis oocytes assessed as potentiation of GABA-induced chloride current at holding potential -70 mV by two-microelectrode voltage clamp technique
[PMID: 21699169]
OVCAR-3 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human OVCAR-3 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
PC-3 IC50
62 μM
Compound: 1
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
Antiproliferative activity against human PC3 cells after 48 hrs by sulforhodamine B assay
[PMID: 22424614]
PC-9 IC50
68.98 μM
Compound: 12; ML
Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay
Antiproliferative activity against human PC9 cells after 72 hrs by MTT assay
[PMID: 30006164]
RAW264.7 IC50
35.4 μM
Compound: 7
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
Inhibition of LPS-induced NO production in mouse RAW264.7 cells after 24 hrs by Griess reagent based assay
[PMID: 24963714]
RAW264.7 IC50
38.9 μM
Compound: 7
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
Inhibition of LPS-induced IL-1beta production in mouse RAW264.7 cells after 24 hrs by ELISA
[PMID: 24963714]
SGC-7901 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human SGC-7901 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
SW480 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human SW480 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
T47D IC50
69.32 μM
Compound: Magnolol
Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
Antiproliferative activity against human T47D cells assessed as inhibition of cell growth incubated for 72 hrs by MTT assay
[PMID: 32791403]
U-251 IC50
> 45 μM
Compound: MAG
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
Antiproliferative activity against human U-251 cells assessed as reduction in cell viability incubated for 24 hrs by CCK-8 assay
[PMID: 32416457]
Vero EC50
3.8 μM
Compound: 19
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
Antiviral activity against SARS coronavirus in Vero E6 cells assessed as inhibition of viral replication by ELISA
[PMID: 17663539]
Vero CC50
68.3 μM
Compound: 19
Cytotoxicity against Vero E6 cells by MTT assay
Cytotoxicity against Vero E6 cells by MTT assay
[PMID: 17663539]
體外研究
(In Vitro)

Magnolol 是 RXRαPPARγ 的雙重激動劑,EC50 值分別為 10.4 μM 和 17.7 μM。Magnolol (26.2 -80 μM) 以劑量依賴性方式與 RXRαLBD 和 PPARγLBD 結(jié)合,Kd 值分別為 45.7 μM 和 1.67 μM。Magnolol (1 -20 μM) 以劑量依賴性方式誘導 PPRE 的轉(zhuǎn)錄,但對 RXRE 轉(zhuǎn)錄沒有活性[1]。Magnolol (1,3,10 μM) 在胰島素存在的情況下增強 3T3-L1 前脂肪細胞和 C3H10T1/2 多能干細胞的脂肪細胞分化。Magnolol (10 μM) 上調(diào)脂肪細胞分化標記基因的 mRNA 表達。Magnolol (1,10 μM) 顯示分化的 3T3-L1 脂肪細胞中基礎(chǔ)和胰島素刺激的葡萄糖攝取增加[2]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

體內(nèi)研究
(In Vivo)

Magnolol (5-15 mg/kg,po) 顯著減輕小鼠中葡聚糖硫酸鈉 (DSS) 誘導的結(jié)腸炎的表型嚴重程度。Magnolol (10、15 mg/kg,口服) 減弱 DSS 處理小鼠結(jié)腸中的組織病理學變化和髓過氧化物酶活性,降低結(jié)腸組織中 DSS 誘導的高水平促炎細胞因子 TNF-α、IL-1β 和 IL-6 . Magnolol (10 mg/kg,po) 還可以逆轉(zhuǎn)小鼠血清代謝組的異常,并調(diào)節(jié)小鼠的色氨酸代謝途徑[3]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

266.33

Formula

C18H18O2

CAS 號
性狀

固體

顏色

White to off-white

中文名稱

厚樸酚

結(jié)構(gòu)分類
初始來源
運輸條件

Room temperature in continental US; may vary elsewhere.

儲存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性數(shù)據(jù)
細胞實驗: 

DMSO 中的溶解度 : 100 mg/mL (375.47 mM; 超聲助溶; 吸濕的 DMSO 對產(chǎn)品的溶解度有顯著影響,請使用新開封的 DMSO)

配制儲備液
濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg
1 mM 3.7547 mL 18.7737 mL 37.5474 mL
5 mM 0.7509 mL 3.7547 mL 7.5095 mL
查看完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內(nèi)使用,-20°C儲存時,請在1個月內(nèi)使用。

  • 摩爾計算器

  • 稀釋計算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質(zhì)量
=
濃度
×
體積
×
分子量 *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

濃度 (start)

C1

×
體積 (start)

V1

=
濃度 (final)

C2

×
體積 (final)

V2

動物實驗:

請根據(jù)您的 實驗動物和給藥方式 選擇適當?shù)娜芙夥桨浮?

以下溶解方案都請先按照 In Vitro 方式配制澄清的儲備液,再依次添加助溶劑:
——為保證實驗結(jié)果的可靠性,澄清的儲備液可以根據(jù)儲存條件,適當保存;體內(nèi)實驗的工作液,建議您現(xiàn)用現(xiàn)配,當天使用;
以下溶劑前顯示的百分比是指該溶劑在您配制終溶液中的體積占比;如在配制過程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過加熱和/或超聲的方式助溶

  • 方案 一

    請依序添加每種溶劑: 10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (9.39 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 400 μL PEG300 中,混合均勻;再向上述體系中加入 50 μL Tween-80,混合均勻;然后再繼續(xù)加入 450 μL 生理鹽水 定容至 1 mL

    生理鹽水的配制:將 0.9 g 氯化鈉,溶解于 ddH?O 并定容至 100 mL,可以得到澄清透明的生理鹽水溶液。
  • 方案 二

    請依序添加每種溶劑: 10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (9.39 mM); 澄清溶液

    此方案可獲得 ≥ 2.5 mg/mL(飽和度未知)的澄清溶液。

    1 mL 工作液為例,取 100 μL 25.0 mg/mL 的澄清 DMSO 儲備液加到 900 μL 20% 的 SBE-β-CD 生理鹽水水溶液 中,混合均勻。

    2 g SBE-β-CD(磺丁基醚 β-環(huán)糊精)粉末定容于 10 mL 的生理鹽水中,完全溶解至澄清透明。
動物溶解方案計算器
請輸入動物實驗的基本信息:

給藥劑量

mg/kg

動物的平均體重

g

每只動物的給藥體積

μL

動物數(shù)量

由于實驗過程有損耗,建議您多配一只動物的量
請輸入您的動物體內(nèi)配方組成:
%
DMSO +
+
%
Tween-80 +
%
Saline
如果您的動物是免疫缺陷鼠或者體弱鼠,建議 DMSO 中的在最后工作液體系中的占比盡量不超過 2%。
方案所需 助溶劑 包括:DMSO, ,均可在 MCE 網(wǎng)站選購。 ,Tween 80,均可在 MCE 網(wǎng)站選購。
計算結(jié)果
工作液所需濃度 : mg/mL
儲備液配制方法 : mg 藥物溶于 μL  DMSO(母液濃度為 mg/mL)。
您所需的儲備液濃度超過該產(chǎn)品的實測溶解度,以下方案僅供參考,如有需要,請與 MCE 中國技術(shù)支持聯(lián)系。
動物實驗體內(nèi)工作液的配制方法 : 取 μL DMSO 儲備液,加入 μL 。 μL ,混合均勻至澄清,再加 μL Tween 80,混合均勻至澄清,再加 μL 生理鹽水。
連續(xù)給藥周期超過半月以上,請謹慎選擇該方案。
請確保第一步儲備液溶解至澄清狀態(tài),從左到右依次添加助溶劑。您可采用超聲加熱 (超聲清洗儀,建議頻次 20-40 kHz),渦旋吹打等方式輔助溶解。
純度 & 產(chǎn)品資料

純度: 99.92%

參考文獻
Kinase Assay
[1]

Binding affinities of magnolol towards purified RXRαLBD and PPARγLBD are analyzed using Biacore 3000 instrument. Proteins are covalently immobilized to CM5 chip using a standard amine-coupling procedure in 10 mM sodium acetate buffer (pH 4.2). The chip is equilibrated with a continuous flow of running buffer (10 mM HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA, 0.005% (v/v) surfactant P20) for 2 hours. Subsequently, magnolol in a gradient of concentrations are injected into the channels at a flow rate of 20 μL/min for 60 seconds, followed by disassociation for 120 seconds. For the coactivator SRC1 recruitment assays, biotin-labelled SRC1 is immobilized to SA chip. Different concentrations of Magnolol are incubated with 5 μM RXRαLBD or PPARγLBD for 1 hour, and then injected to the channel at a flow rate of 20 μL/min for 60 s, followed by disassociation for 120 s[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay
[2]

For differentiation of 3T3-L1 pre-adipocytes, at 2 days after confluence (defined as day 0), cells are incubated in differentiation medium containing 0.5 mM IBMX, 10 μg/mL insulin and 0.25 μM DEX in DMEM containing 10% fetal bovine serum (FBS). After 2 days, the cell culture medium is changed to DMEM containing 10 μg/mL insulin and 10% FBS. The medium is replaced again with fresh DMEM containing 10% FBS after 2 days. Adipocytes are used 6-8 days after the initiation of differentiation. In adipogenesis studies, 3T3-L1 pre-adipocytes and C3H10T1/2 pluripotent stem cells grown in DMEM supplemented with 10% bovine calf serum (day 0) are treated with insulin (1 μg/mL) with/without Magnolol in 10% FBS contained DMEM at the indicated concentration for 9 days. Fresh medium containing insulin (1 μg/mL) and 10% FBS with/without magnolol is replenished every 3 days[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration
[3]

Experimental colitis mice model is induced by routine administration of dextran sulfate sodium (DSS) solution dissolved in drinking distilled water at a concentration of 2.0% (w/v) ad libitum for 5 consecutive days. Distilled water is given to mice in the normal group for the same period. The body weight of each mice is recorded daily in the morning (9:00 a.m.). On day 6, the mice with significant body weight loss, diarrhea, and gross bleeding are considered as experimental candidates of colitis. All the mice with comparable disease index are then randomly divided into 5 groups (n = 8/group): (1) DSS model group, intragastric administrated with saline; (2) positive control group, intraperitoneal injected with infliximab (5 mg/kg); (3) low dose treatment group, intragastric administrated with Magnolol (5 mg/kg); (4) medium dose treatment group, intragastric administrated with Magnolol (10 mg/kg); (5) high dose treatment group, intragastric administrated with Magnolol (15 mg/kg). The mice in control group receives drinking water without DSS throughout the entire experimental period and intragastric administrated with saline[3].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

參考文獻

完整儲備液配制表

* 請根據(jù)產(chǎn)品在不同溶劑中的溶解度選擇合適的溶劑配制儲備液;一旦配成溶液,請分裝保存,避免反復凍融造成的產(chǎn)品失效。
儲備液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C儲存時,請在6個月內(nèi)使用,-20°C儲存時,請在1個月內(nèi)使用。

可選溶劑 濃度 溶劑體積 質(zhì)量 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 3.7547 mL 18.7737 mL 37.5474 mL 93.8685 mL
5 mM 0.7509 mL 3.7547 mL 7.5095 mL 18.7737 mL
10 mM 0.3755 mL 1.8774 mL 3.7547 mL 9.3869 mL
15 mM 0.2503 mL 1.2516 mL 2.5032 mL 6.2579 mL
20 mM 0.1877 mL 0.9387 mL 1.8774 mL 4.6934 mL
25 mM 0.1502 mL 0.7509 mL 1.5019 mL 3.7547 mL
30 mM 0.1252 mL 0.6258 mL 1.2516 mL 3.1290 mL
40 mM 0.0939 mL 0.4693 mL 0.9387 mL 2.3467 mL
50 mM 0.0751 mL 0.3755 mL 0.7509 mL 1.8774 mL
60 mM 0.0626 mL 0.3129 mL 0.6258 mL 1.5645 mL
80 mM 0.0469 mL 0.2347 mL 0.4693 mL 1.1734 mL
100 mM 0.0375 mL 0.1877 mL 0.3755 mL 0.9387 mL
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

您最近查看的產(chǎn)品:

Your information is safe with us. * Required Fields.

   產(chǎn)品名稱:

 

* 需求量:

* 客戶姓名:

 

* Email:

* 電話:

 

* 公司或機構(gòu)名稱:

   留言給我們:

Bulk Inquiry

Inquiry Information

產(chǎn)品名稱:
Magnolol
目錄號:
HY-N0163
需求量: